Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie Inc.

www.abbvie.com

Latest From AbbVie Inc.

JAK Inhibitors Have Dupixent In Their Sights For Atopic Dermatitis

Analysts predict that Sanofi and Regeneron's Dupixent is going to dominate the severe eczema market but the oral options of Lilly/Incyte's baricitinib and AbbVie's upadacitinib are progressing through the pipeline to make a challenge.

Immune Disorders Dermatology

MURANO To Drive AbbVie/Roche's Venetoclax In CLL

Top-line MURANO data support Venclexta's current conditional approvals and expand its use into a broader population that should radically boost sales.

Clinical Trials Companies

Pipeline Watch: Phase III Readouts For ADV7103, Pembrolizumab, Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

J&J's Guselkumab Nears Crowded EU Psoriasis Market After CHMP OK

Janssen-Cilag/MorphoSys's potential first-in-class psoriasis therapy has received a positive approval recommendation from Europe's top scientific advisory panel, and could become a blockbuster product despite the cluttered and changeable state of the dermatology sector.

Approvals Biologics
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Big Pharma
  • Parent & Subsidiaries
  • AbbVie Inc.
  • Senior Management
  • Richard A Gonzalez, Chmn. & CEO
    William J Chase, EVP, CFO
    Michael Servino, MD, EVP, R&D & CSO
    Carlos Alban, EVP, Commercial Ops.
  • Contact Info
  • AbbVie Inc.
    Phone: (847) 937-6100
    1 N. Waukegan Rd.
    North Chicago, IL 60064
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register